Labiotech.eu

News and Trends 11 Oct 2022

Late-breaking data shows significant remission in children with EoE

Late-breaking positive results from a phase 3 trial have shown that children with eosinophilic esophagitis (EoE) given a higher dose of Dupixent showed histological disease remission and signs of weight gain. At week 16, 68% of children aged one to 11 years with active EoE on the higher dose displayed the positive results during the […]

October 11, 2022 - 3 minutesmins - By Liza Laws

News and Trends 11 Oct 2022

TILT Biotherapeutics doses first U.S. patient in ovarian cancer immunotherapy trial

TILT Biotherapeutics says the first U.S. patient has been dosed in its ovarian cancer trial using its oncolytic adenovirus, TILT-123. The company said TILT-123 has the potential to be first-in-class for this indication. The open-label, phase I, dose-escalation, multicenter, and multinational, clinical trial of TILT-123 in combination with MSD’s (a tradename of Merck & Co., […]

October 11, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 11 Oct 2022

Illumina and AstraZeneca look to drug target discovery with ‘pivotal research collaboration’

Illumina Inc. has announced a strategic research collaboration with AstraZeneca to accelerate drug target discovery by combining their work in artificial intelligence (AI) based genome interpretation and genomic analysis techniques along with industry expertise. The collaboration will evaluate whether a combined framework of these technologies can increase the yield and confidence of target discovery to […]

October 11, 2022 - 2 minutesmins - By Jim Cornall

shutterstock idiopathic pulmonary fibrosis

More News! 11 Oct 2022

First patient dosed in study of idiopathic pulmonary fibrosis

Redx, a clinical-stage biotech company, is trialing RXC007, a wholly owned rho associated coiled-coil containing protein kinase 2 (ROCK2) selective inhibitor as a potential treatment for patients with idiopathic pulmonary fibrosis (IPF). The phase 2a study is a 12-week multi-cohort, randomized, double-blind, placebo-controlled dose ranging study to assess early signals of efficacy as well as […]

October 11, 2022 - 3 minutesmins - By Liza Laws

News and Trends 11 Oct 2022

Accelerated application for drug to help immunodeficiency submitted by Pharming

A marketing authorization application (MAA) has been submitted by Dutch company Pharming Group, to the European Medicines Agency (EMA) for a rare, primary immunodeficiency in adults and adolescents 12 years and older. Activated phosphonide 3-kinase delta syndrome (APDS), first discovered in 2013, is caused by genetic variants in either one of two identified genes known […]

October 11, 2022 - 4 minutesmins - By Liza Laws

News and Trends 11 Oct 2022

License granted to EnteroBiotix for manufacture of microbiome product candidates

Microbiome therapeutics company, EnteroBiotix Limited has been granted a manufacturer’s license for a GMP manufacturing facility for Investigational Medicinal Products (IMP) to make microbiome product candidates for clinical trials. It was given by the Medicines and Healthcare Products Regulatory Agency (MHRA) and also incorporates an in-house QC hub and analytical department. EnteroBiotix’s manufacturing capabilities include […]

October 11, 2022 - 2 minutesmins - By Liza Laws

News and Trends 11 Oct 2022

Gedea Biotech reports results from bacterial vaginosis trial

Gedea Biotech has reported top-line results from a clinical study, NEFERTITI, of its lead product, pHyph, a vaginal tablet for topical treatment of bacterial vaginosis (BV). NEFERTITI is a placebo-controlled, double blind clinical trial performed in Sweden and UK in 150 patients. Treatment details The treatment is a vaginal tablet taken once daily for six […]

October 11, 2022 - 4 minutesmins - By Jim Cornall

Anastasiia Slynko biotech investment 744x368 1

In Depth 11 Oct 2022

The biggest private biotech investments in September 2022

The companies Acelyrin, InnovaFeed and Arsenal Biosciences bagged the biggest biotech investments in September 2022, with insect protein and cell therapies attracting big funding rounds. Autumn is in full swing in the Northern Hemisphere. After a breather in August 2022, September saw the return of big fundraising activity for biotech companies. We’ve gathered the biggest […]

October 11, 2022 - 3 minutesmins - By Jonathan Smith

News and Trends 11 Oct 2022

Muna Therapeutics gets $4.9M grant for Parkinson’s disease research

Muna Therapeutics has been awarded a $4.9 million grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF). The grant will be used to support ongoing preclinical research and development of novel, brain-exposed, small molecule potassium channel type 1.3 (Kv1.3) blockers to abrogate neuroinflammation driven by disease-associated microglia and enhance neuroprotection as a disease-modifying […]

October 11, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 11 Oct 2022

Positive results from NMD Pharma myasthenia gravis trial

NMD Pharma A/S has reported positive top-line results from its phase I/IIa clinical trial of NMD670, recently granted orphan drug designation by the FDA for treatment of myasthenia gravis (MG). NMD670 was safe and well tolerated in healthy volunteers and patients. Administration of single doses of NMD670 was associated with clinically significant improvements in the […]

October 11, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 11 Oct 2022

Clinical Microbiomics expanding with €10M million investment

Danish microbiome research company Clinical Microbiomics A/S has received €10 million ($9.7 million) in funding from Seventure Partners. Clinical Microbiomics, founded in 2015, is a microbiome analysis company, which includes work on clonal-level microbiome profiling. The company is working with food and consumer health companies and is supporting the pharmaceutical industry in phase 3 clinical […]

October 11, 2022 - 2 minutesmins - By Jim Cornall

More News! 10 Oct 2022

Positive data indicates likely therapeutic effect of Alzheimer’s drug

Positive phase 2a clinical data from an Alzheimer’s disease (AD) biomarker study, has been announced today (October 10). Actinogen Medical Limited shared the news that its study validates its planned program for Xanamem, a potential drug for the disease. The biomarker study was conducted in 72 patients with available blood biomarker samples from the prior […]

October 10, 2022 - 3 minutesmins - By Liza Laws

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Late-breaking data shows significant remission in children with EoE

TILT Biotherapeutics doses first U.S. patient in ovarian cancer immunotherapy trial

Illumina and AstraZeneca look to drug target discovery with ‘pivotal research collaboration’

First patient dosed in study of idiopathic pulmonary fibrosis

Accelerated application for drug to help immunodeficiency submitted by Pharming

License granted to EnteroBiotix for manufacture of microbiome product candidates

Gedea Biotech reports results from bacterial vaginosis trial

The biggest private biotech investments in September 2022

Muna Therapeutics gets $4.9M grant for Parkinson’s disease research

Positive results from NMD Pharma myasthenia gravis trial

Clinical Microbiomics expanding with €10M million investment

Positive data indicates likely therapeutic effect of Alzheimer’s drug

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!